NCT06177405View on ClinicalTrials.gov

Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions

Rheumatoid Arthritis

Interventions

DRUG

genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors

drug therapy

Trial Locations (1)

Unknown

IBMC, Moscow

All Listed Sponsors

collaborator

Moscow Regional Research and Clinical Institute (MONIKI)

OTHER_GOV

lead

Institute of Biomedical Chemistry, Russia

OTHER

NCT06177405 - Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors | Biotech Hunter | Biotech Hunter